Study Demonstrates Benefits Of Pradaxa Are Maintained For Over Four Years

New data from the RELY-ABLE study have provided additional support to the safety profile and efficacy of Pradaxa(R) (dabigatran etexilate) for stroke prevention in patients with nonvalvular atrial fibrillation (AF) over a period in excess of 2 years.[*][1] The new long-term results presented at the American Heart Association's (AHA) Scientific Sessions, are consistent with the findings from the RE-LY trial[*]. The rates of stroke and haemorrhage observed during an additional 2.3 years of blinded follow-up in RELY-ABLE correspond to the initial RE-LY results, with the benefit of both doses of dabigatran etexilate sustained throughout the study's duration.[1]-[3]  read more

Read the whole article on

More from